

ReSearch Pharmaceutical Services, Inc.
Continued Trading on AIM

ReSearch Pharmaceutical Services, Inc. (“RPS” or the “Company”), a leading provider of integrated clinical development outsourcing solutions to the bio-pharmaceutical industry, announces that its common stock will continue to trade on AIM beyond September 1, 2008. Previously the Company had announced that it would cancel trading of its common stock on AIM on September 1, 2008.

As a United States based company, the Company believes that a listing in the United States would, over time, increase the liquidity of its common stock and improve its potential access to United States based investors. The Company has received approval from its stockholders at its Annual Meeting to cancel its common stock from trading on AIM in anticipation of becoming listed in the United States.

In accordance with this authority, the Company reserves the right to cancel its common stock from trading on AIM at any time on or prior to December 31, 2008, subject to the Company publicly announcing the date of cancellation at least 10 business days prior to the intended date of cancellation of the common stock. Absent of such announcement, the Company’s common stock and warrants will remain admitted to trading on AIM.

As previously disclosed, if the common stock’s admission to trading on AIM is cancelled, the Company’s nominated adviser has indicated that it will resign and therefore trading of the warrants will be suspended and, if within one month the Company has not appointed another nominated adviser, the admission of the warrants to trading on AIM will also be cancelled. The Company currently does not intend to appoint a new nominated advisor if the common stock are cancelled from trading.

The Company will not cancel its common stock from trading on AIM if the Board determines that remaining admitted to trading on AIM is in the best interests of stockholders and warrant holders.

For further information please contact:

ReSearch Pharmaceutical Services, Inc.:

+1-215-540-0700

Daniel M. Perlman, Chairman & Chief Executive Officer

Steven Bell, Chief Financial Officer

Nominated Adviser and UK Broker:

+44-20-7012-2100

Arbuthnot Securities Limited

James Steel/Richard Tulloch